Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation

for the New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Women progress to death at the same rate as men despite lower plasma HIV RNA (viral load). We investigated sexspecific differences in immune activation and inflammation as a potential explanation. Methods: Inflammatory and immune activation markers [interferon-γ, tumor necrosis factor (TNF) α, IL-6, IL-18, IFN-γ- induced protein 10, C-reactive protein (CRP), lipopolysaccharide, and sCD14] were measured at weeks 0, 24, and 48 after combination antiretroviral therapy (cART) in a random subcohort (n = 215) who achieved virologic suppression in ACTG A5175 (Prospective Evaluation of Antiretrovirals in Resource-Limited Settings). Association between sex and changes in markers postcART was examined using random effects models. Average marker differences and 95% confidence intervals were estimated using multivariable models. Results: At baseline, women had lower median log10 viral load (4.93 vs 5.18 copies per milliliter, P = 0.01), CRP (2.32 vs 4.62 mg/L, P = 0.01), detectable lipopolysaccharide (39% vs 55%, P = 0.04), and sCD14 (1.9 vs 2.3 μg/mL, P = 0.06) vs men. By week 48, women had higher interferon -γ (22.4 vs 14.9 pg/mL, P = 0.05), TNF-α (11.5 vs 9.5 pg/mL, P = 0.02), and CD4 (373 vs 323 cells per cubic millimeter, P = 0.02). In multivariate analysis, women had greater increases in CD4 and TNF-α but less of a decrease in CRP and sCD14 compared with men. Conclusions: With cART-induced viral suppression, women have less reduction in key markers of inflammation and immune activation compared with men. Future studies should investigate the impact of these sex-specific differences on morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)123-129
Number of pages7
JournalJournal of acquired immune deficiency syndromes (1999)
Volume73
Issue number2
DOIs
StatePublished - Oct 1 2016

Fingerprint

Sex Characteristics
Biomarkers
C-Reactive Protein
Tumor Necrosis Factor-alpha
Viral Load
Interferons
Lipopolysaccharides
Inflammation
Therapeutics
Interleukin-18
Protein C
Interleukin-6
Multivariate Analysis
HIV
RNA
Confidence Intervals
Morbidity
Mortality

Keywords

  • Antiretroviral treatment
  • HIV
  • Immune activation
  • Inflammation
  • Sex
  • Women

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation. / for the New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams.

In: Journal of acquired immune deficiency syndromes (1999), Vol. 73, No. 2, 01.10.2016, p. 123-129.

Research output: Contribution to journalArticle

for the New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams. / Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation. In: Journal of acquired immune deficiency syndromes (1999). 2016 ; Vol. 73, No. 2. pp. 123-129.
@article{d511e0716ac943c5a2cf92e88b8c5f1f,
title = "Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation",
abstract = "Background: Women progress to death at the same rate as men despite lower plasma HIV RNA (viral load). We investigated sexspecific differences in immune activation and inflammation as a potential explanation. Methods: Inflammatory and immune activation markers [interferon-γ, tumor necrosis factor (TNF) α, IL-6, IL-18, IFN-γ- induced protein 10, C-reactive protein (CRP), lipopolysaccharide, and sCD14] were measured at weeks 0, 24, and 48 after combination antiretroviral therapy (cART) in a random subcohort (n = 215) who achieved virologic suppression in ACTG A5175 (Prospective Evaluation of Antiretrovirals in Resource-Limited Settings). Association between sex and changes in markers postcART was examined using random effects models. Average marker differences and 95{\%} confidence intervals were estimated using multivariable models. Results: At baseline, women had lower median log10 viral load (4.93 vs 5.18 copies per milliliter, P = 0.01), CRP (2.32 vs 4.62 mg/L, P = 0.01), detectable lipopolysaccharide (39{\%} vs 55{\%}, P = 0.04), and sCD14 (1.9 vs 2.3 μg/mL, P = 0.06) vs men. By week 48, women had higher interferon -γ (22.4 vs 14.9 pg/mL, P = 0.05), TNF-α (11.5 vs 9.5 pg/mL, P = 0.02), and CD4 (373 vs 323 cells per cubic millimeter, P = 0.02). In multivariate analysis, women had greater increases in CD4 and TNF-α but less of a decrease in CRP and sCD14 compared with men. Conclusions: With cART-induced viral suppression, women have less reduction in key markers of inflammation and immune activation compared with men. Future studies should investigate the impact of these sex-specific differences on morbidity and mortality.",
keywords = "Antiretroviral treatment, HIV, Immune activation, Inflammation, Sex, Women",
author = "{for the New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams} and Mathad, {Jyoti S.} and Nikhil Gupte and Ashwin Balagopal and David Asmuth and James Hakim and Breno Santos and Cynthia Riviere and Mina Hosseinipour and Patcharaphan Sugandhavesa and Rosa Infante and Sandy Pillay and Cardoso, {Sandra W.} and Noluthando Mwelase and Jyoti Pawar and Sima Berendes and Nagalingeswaran Kumarasamy and Andrade, {Bruno B.} and Campbell, {Thomas B.} and Currier, {Judith S.} and Cohn, {Susan E.} and Amita Gupta",
year = "2016",
month = "10",
day = "1",
doi = "10.1097/QAI.0000000000001095",
language = "English (US)",
volume = "73",
pages = "123--129",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation

AU - for the New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams

AU - Mathad, Jyoti S.

AU - Gupte, Nikhil

AU - Balagopal, Ashwin

AU - Asmuth, David

AU - Hakim, James

AU - Santos, Breno

AU - Riviere, Cynthia

AU - Hosseinipour, Mina

AU - Sugandhavesa, Patcharaphan

AU - Infante, Rosa

AU - Pillay, Sandy

AU - Cardoso, Sandra W.

AU - Mwelase, Noluthando

AU - Pawar, Jyoti

AU - Berendes, Sima

AU - Kumarasamy, Nagalingeswaran

AU - Andrade, Bruno B.

AU - Campbell, Thomas B.

AU - Currier, Judith S.

AU - Cohn, Susan E.

AU - Gupta, Amita

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: Women progress to death at the same rate as men despite lower plasma HIV RNA (viral load). We investigated sexspecific differences in immune activation and inflammation as a potential explanation. Methods: Inflammatory and immune activation markers [interferon-γ, tumor necrosis factor (TNF) α, IL-6, IL-18, IFN-γ- induced protein 10, C-reactive protein (CRP), lipopolysaccharide, and sCD14] were measured at weeks 0, 24, and 48 after combination antiretroviral therapy (cART) in a random subcohort (n = 215) who achieved virologic suppression in ACTG A5175 (Prospective Evaluation of Antiretrovirals in Resource-Limited Settings). Association between sex and changes in markers postcART was examined using random effects models. Average marker differences and 95% confidence intervals were estimated using multivariable models. Results: At baseline, women had lower median log10 viral load (4.93 vs 5.18 copies per milliliter, P = 0.01), CRP (2.32 vs 4.62 mg/L, P = 0.01), detectable lipopolysaccharide (39% vs 55%, P = 0.04), and sCD14 (1.9 vs 2.3 μg/mL, P = 0.06) vs men. By week 48, women had higher interferon -γ (22.4 vs 14.9 pg/mL, P = 0.05), TNF-α (11.5 vs 9.5 pg/mL, P = 0.02), and CD4 (373 vs 323 cells per cubic millimeter, P = 0.02). In multivariate analysis, women had greater increases in CD4 and TNF-α but less of a decrease in CRP and sCD14 compared with men. Conclusions: With cART-induced viral suppression, women have less reduction in key markers of inflammation and immune activation compared with men. Future studies should investigate the impact of these sex-specific differences on morbidity and mortality.

AB - Background: Women progress to death at the same rate as men despite lower plasma HIV RNA (viral load). We investigated sexspecific differences in immune activation and inflammation as a potential explanation. Methods: Inflammatory and immune activation markers [interferon-γ, tumor necrosis factor (TNF) α, IL-6, IL-18, IFN-γ- induced protein 10, C-reactive protein (CRP), lipopolysaccharide, and sCD14] were measured at weeks 0, 24, and 48 after combination antiretroviral therapy (cART) in a random subcohort (n = 215) who achieved virologic suppression in ACTG A5175 (Prospective Evaluation of Antiretrovirals in Resource-Limited Settings). Association between sex and changes in markers postcART was examined using random effects models. Average marker differences and 95% confidence intervals were estimated using multivariable models. Results: At baseline, women had lower median log10 viral load (4.93 vs 5.18 copies per milliliter, P = 0.01), CRP (2.32 vs 4.62 mg/L, P = 0.01), detectable lipopolysaccharide (39% vs 55%, P = 0.04), and sCD14 (1.9 vs 2.3 μg/mL, P = 0.06) vs men. By week 48, women had higher interferon -γ (22.4 vs 14.9 pg/mL, P = 0.05), TNF-α (11.5 vs 9.5 pg/mL, P = 0.02), and CD4 (373 vs 323 cells per cubic millimeter, P = 0.02). In multivariate analysis, women had greater increases in CD4 and TNF-α but less of a decrease in CRP and sCD14 compared with men. Conclusions: With cART-induced viral suppression, women have less reduction in key markers of inflammation and immune activation compared with men. Future studies should investigate the impact of these sex-specific differences on morbidity and mortality.

KW - Antiretroviral treatment

KW - HIV

KW - Immune activation

KW - Inflammation

KW - Sex

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84973307889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973307889&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001095

DO - 10.1097/QAI.0000000000001095

M3 - Article

C2 - 27258230

AN - SCOPUS:84973307889

VL - 73

SP - 123

EP - 129

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 2

ER -